Home Cart Sign in  
Chemical Structure| 33818-15-4 Chemical Structure| 33818-15-4

Structure of Citicoline sodium salt
CAS No.: 33818-15-4

Chemical Structure| 33818-15-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Citicoline Sodium is an essential component of cell membrane phospholipids. Citicoline (CDP-choline or cytidinediphosphate choline; cytidine 5′-diphosphocholine) is a complex organic molecule composed of ribose, pyrophosphate, cytosine and choline. Citicoline is very water soluble and has a bioavailability of greater than 90%. Citicoline presented no mitogenic and chemotactic effects on hCMEC/D3; however, it significantly increased wound recovery, spheroid sprouting and strongly induced endothelial tube-like structure formation in Matrigel. Citicoline induced the expression of phospho-extracellular-signal regulated kinase (ERK)-1/2. It protects hCMEC/D3 against cell damage/apoptosis. Citicoline induces angiogenesis and improves survival of human brain microvessel endothelial cells through pathways involving p-ERK1/2, and IRS-1.

Synonyms: Citicoline sodium; Cytidine diphosphate-choline sodium; Citicoline Na

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Citicoline sodium salt

CAS No. :33818-15-4
Formula : C14H25N4NaO11P2
M.W : 510.31
SMILES Code : O[C@H]1[C@@H](O[C@@H]([C@H]1O)COP(OP(OCC[N+](C)(C)C)([O-])=O)([O-])=O)N2C(N=C(C=C2)N)=O.[Na+]
Synonyms :
Citicoline sodium; Cytidine diphosphate-choline sodium; Citicoline Na
MDL No. :MFCD00037486

Safety of Citicoline sodium salt

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hypothalamic HypoE22 cells 1 nM–10 µM 24 h To evaluate biocompatibility, results showed no significant effect on cell viability within the concentration range of 1 nM–10 µM, indicating biocompatibility of Citicoline, vitamin B3, and CAVAQ10®. Nutrients. 2022 Jul 20;14(14):2963

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male CD-1 Swiss albino mice Unilateral, laser-induced ocular hypertension (OHT) model Oral 500 mg/kg Once daily, starting 15 days before laser treatment, continuing until sacrifice (7 days post-laser) To evaluate the neuroprotective effects of the combination of Citicoline and CoQ10 on retinal ganglion cells (RGCs) and visual pathway neurons in a laser-induced ocular hypertension model. Results showed that the Citicoline + CoQ10 group exhibited a hypotensive effect at 24 h post-laser, prevented Brn3a+ RGC death in OHT eyes, but did not affect NeuN+ neurons in the dLGN. Antioxidants (Basel). 2024 Dec 24;14(1):4
Male adult Sprague Dawley rats High-fat diet (HFD) and streptozotocin (STZ)-induced non-alcoholic steatohepatitis (NASH) model Intraperitoneal injection 250 mg/kg and 500 mg/kg Once daily for eight weeks Citicoline alone or in combination with Lactobacillus improved histopathological NASH outcomes and reversed all molecular pathological alterations linked to NASH by upregulating Nrf2/HO-1 expression and downregulating TLR4/NF-kB signaling pathways. AMB Express. 2023 Jun 8;13(1):57
Wistar rats Reversible focal cerebral ischemia model Intraperitoneal injection 500 mg/kg 15 min after the start of reperfusion and then after 24 h Citicoline demonstrated a pronounced neuroprotective effect, reduced the infarct size, and improved neurological deficits Cells. 2020 Aug 8;9(8):1860

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02823106 Ischemic Stroke Phase 1 Withdrawn(Study put on clinica... More >>l hold by FDA. Sponsor decided to no pursue the study.) Less << - United States, Kentucky ... More >> University of Kentucky Medical Center Lexington, Kentucky, United States, 40536 Less <<
NCT01591759 Traumatic Brain Injury Phase 2 Withdrawn(Our citicoline suppl... More >>y expired and the exact product has discontinued.) Less << - United States, Massachusetts ... More >> McLean Hospital Brain Imaging Center Belmont, Massachusetts, United States, 02478-9106 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.80mL

1.96mL

0.98mL

19.60mL

3.92mL

1.96mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories